<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849859</url>
  </required_header>
  <id_info>
    <org_study_id>REC.61-096-21-1</org_study_id>
    <nct_id>NCT03849859</nct_id>
  </id_info>
  <brief_title>Single Versus Multiple Plastic Stents in Malignant Distal Bile Duct Obstruction</brief_title>
  <official_title>A Prospective Randomized Trial Comparing Single Plastic Stent Versus Multiple Plastic Stents in Inoperable Malignant Distal Bile Duct Obstruction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic retrograde cholangiopancreatography (ERCP) with biliary stent placement is crucial
      for palliative treatment in patients with malignant bile duct obstruction who cannot perform
      surgery due to advanced diseases or associated comorbidities. Stent patency is challenge in
      ERCP. Self expanding metallic stents (SEMS) have a longer duration of patency and fewer of
      recurrence occlusion of stent when compared with plastic stent (PS). However, the cost of MS
      is more expensive than PS about 4 times. Therefore, many patients cannot afford the MS due to
      their economic status. Data regarding the efficacy and safety of multiple PS compared with
      single PS for the palliative treatment in unresectable malignant distal bile duct obstruction
      are limited.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the current study is to compare the cumulative stent patency of multiple PS and
      single plastic stent and the clinical success rate as a primary objective, investigate the
      technical success rate, procedure time incident of overall adverse events including stent
      dysfunction and overall procedure related mortality as secondary outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative stent patency</measure>
    <time_frame>From the date of randomization though the study completion, assessed up to 1 year.</time_frame>
    <description>Proportion of patients with documented stent dysfunction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical success rate</measure>
    <time_frame>Four weeks after randomization</time_frame>
    <description>Proportion of patients with total bilirubin level declining &gt; 50 % of the initial value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall adverse events</measure>
    <time_frame>From the date of randomization until the date of documented adverse events, assessed up to 1 month.</time_frame>
    <description>Proportion of patients develop adverse events associated procedure included pancreatitis, cholangitis, hemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall patient survival</measure>
    <time_frame>From the date of randomization until the date of death from any cause, assessed up to 12 months.</time_frame>
    <description>Proportion of patients who die from any causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure relate death</measure>
    <time_frame>From the date of randomization until the date of death from procedure within 7 days</time_frame>
    <description>Proportion of patients who die from complications related procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>From the date of randomization until the last stent deploy, assessed up to 1 day.</time_frame>
    <description>Proportion of patient who successful underwent stent placement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Plastic Stent Occlusion</condition>
  <arm_group>
    <arm_group_label>Single plastic stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deployment of single plastic stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple plastic stents</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deployment of multiple plastic stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Single plastic stent</intervention_name>
    <description>Deployment of single plastic stent</description>
    <arm_group_label>Single plastic stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multiple plastic stents</intervention_name>
    <description>Deployment of multiple plastic stents</description>
    <arm_group_label>Multiple plastic stents</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In-operable distal malignant bile duct obstruction Age&gt;18

        Exclusion Criteria:

        Pregnancy ECOG 3-4 Can not correct coagulopathy Contraindicate for ERCP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ni Netinatsunton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKC Institute of Gastroenterology and Hepatology.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nisa Netinartsuntorn, M.D.</last_name>
    <phone>8874451965</phone>
    <phone_ext>9</phone_ext>
    <email>nisasan@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bancha Ovartlanporn, Asso.prof</last_name>
    <phone>8874451965</phone>
    <phone_ext>9</phone_ext>
    <email>mrovartji-net@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NKC Institues of Gastroenterology and Hepatology, Prince of Songkla University</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NKC Institue of Gastroenterology and Hepatology, Prince of Songkla University</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr. Nisa Netinatsunton, MD</last_name>
      <phone>8874451965</phone>
      <phone_ext>9</phone_ext>
      <email>nisasan@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Dr.Bancha Ovartalaporn, MD</last_name>
      <phone>8874451965</phone>
      <phone_ext>9</phone_ext>
      <email>mrovartji-net@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nisa Netinatsunton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Nisa Netinatsunton</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Plastic stent</keyword>
  <keyword>Endoscopic Retrograde Cholangiopancreatography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

